ERC Advanced Grant · 2023
RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming
Cancer immunotherapy achieves unprecedented efficacy against a number of malignant diseases. Preclinical experiments in mouse models conclude that type-1 dendritic cells (cDC1) that present tumor antigens are an absolute requirement for most immunotherapy strategies to be efficacious, including those routinely applied to cancer patients at present. cDC1 cells are specialized in redirecting engulfed cell-associated antigens to the class I MHC antigen-presentation pathway in the context of IL-12 production and co-stimulation, at least when cDC1 cells are in the presence of moieties denoting viral infection. Such phenomena are key to prime anti-tumor T lymphocytes through a mechanism known as…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at Foundation for Applied Medical Investigation - University of Navarra